The latest announcement is out from CytoMed Therapeutics Limited ( (GDTC) ).
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
CytoMed Therapeutics has entered a collaboration with SunAct Cancer Institute in India to advance the use of its allogeneic gamma delta T cells in a Phase 2 clinical trial aimed at treating solid cancers. This partnership seeks to explore the therapy’s safety and efficacy, potentially providing an affordable treatment option for cancer patients in India, while contributing to global cancer research data.
More about CytoMed Therapeutics Limited
CytoMed Therapeutics Limited is a Singapore-based clinical stage biopharmaceutical company that develops novel donor-derived cell-based allogeneic immunotherapies for cancer treatment. They focus on leveraging proprietary technologies, including gamma delta T cell and gamma delta Natural Killer T cell therapies, to address the limitations of existing CAR-T therapies in treating solid tumors.
YTD Price Performance: -1.43%
Average Trading Volume: 22,865
Technical Sentiment Consensus Rating: Strong Sell
Current Market Cap: $39.81M
See more data about GDTC stock on TipRanks’ Stock Analysis page.
